N
Namenda
Manufacturers of Namenda and generic Alzheimer’s medications settled for over $56 million over price-fixing claims.
ClosedSelected statesClaim status: Closed on February 3, 2023Payout: VariesNo longer claimable
About this settlement
The case involves allegations of price-fixing for Namenda IR and XR medications and their generic equivalents.
This settlement resolves claims that manufacturers of brand-name and generic Namenda Alzheimer’s medications conspired to fix prices, resulting in over $56 million paid to affected purchasers.
Who qualifies
- Third-party payors who indirectly purchased branded Namenda IR 5 or 10 mg tablets, AB-rated generic equivalents, or Namenda XR capsules in specified states between June 1, 2012...
- Persons or entities who indirectly purchased branded Namenda IR or XR since April 14, 2010.
Varies
Claim status: Closed on February 3, 2023